Novartis: Melanoma trials

The registry lists 53 Melanoma studies with Novartis as lead sponsor. 1 are open to participants now and 18 have results posted.

Phase 1 19Phase 2 17Phase 3 6Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Dabrafenib and/or Trametinib Rollover StudyRecruitingNCT03340506Phase 4
• Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related OutcomesCompletedNCT03551626Phase 3Results posted
• Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaCompletedNCT03484923Phase 2Results posted
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedNCT03207867Phase 2Results posted
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaTerminatedNCT02967692Phase 3Results posted
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesCompletedNCT02807844Phase 1/2Results posted
• A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.TerminatedNCT02711345Phase 1Results posted
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedNCT02608268Phase 1/2Results posted
• Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02460224Phase 1/2Results posted
• Phase I/II Study of PDR001 in Patients With Advanced MalignanciesCompletedNCT02404441Phase 1/2Results posted
• Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaCompletedNCT02083354Phase 2Results posted
• Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainCompletedNCT02039947Phase 2Results posted
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibCompletedNCT01831726Phase 2Results posted
• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).CompletedNCT01682083Phase 3Results posted
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedNCT01597908Phase 3Results posted
• A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaCompletedNCT01584648Phase 3Results posted
• Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212CompletedNCT01072175Phase 2Results posted
• A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit MutationCompletedNCT01028222Phase 2Results posted
• Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic MelanomaCompletedNCT00414765Phase 4Results posted
• A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in JapanCompletedNCT07649252
• Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®TerminatedNCT06587451Phase 3
• Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV MelanomaCompletedNCT06557291
• Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma PatientsCompletedNCT06369428
• A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive MelanomaCompletedNCT06337617
• Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic MelanomaCompletedNCT06251934
• A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaCompletedNCT06153238Phase 1
• Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma PatientsCompletedNCT05984615
• Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of MelanomaCompletedNCT05874817
• Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + BinimetinibTerminatedNCT05848219
• Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma PatientsCompletedNCT05806268
• Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of MelanomaCompletedNCT05714371
• Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor BurdenCompletedNCT05611229
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasActive, not recruitingNCT05415072Phase 1/2
• Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.CompletedNCT04961619
• Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete ResectionActive, not recruitingNCT04666272
• Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)CompletedNCT04547946
• Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical ResectionNo longer availableNCT04544202
• Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic MelanomaNo longer availableNCT04489433
• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaActive, not recruitingNCT04417621Phase 2
• A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTerminatedNCT04261439Phase 1
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.Active, not recruitingNCT03891953Phase 1
• Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedNCT03301896Phase 1
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminatedNCT03114319Phase 1
• A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1
• Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsTerminatedNCT02607813Phase 1
• A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell CarcinomaCompletedNCT01652547Phase 1
• A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsCompletedNCT01351103Phase 1
• A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic MelanomaCompletedNCT00304525Phase 1/2
• Safety of TKI258 in Advanced/Metastatic Melanoma SubjectsCompletedNCT00303251Phase 1/2
• Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
• EPO906 Therapy in Patients With Advanced MelanomaCompletedNCT00035165Phase 2
• Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1